A wide variety of differentially expressed tumor-associated antigens have been identified within malignancies (e.g., BCMA, CD19, GD2, and Mesothelin) which can be selectively targeted by the CAR depending on tumor expression profile (115–117). This evidence concerns the gene CD19 and neoplasm.